Clinical Trial Update: A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG [Phase 2, Phase 3]

View source ↗

Summary

This entry notes an ongoing Phase 2/Phase 3 trial evaluating weekly GLM101 for PMM2-congenital disorder of glycosylation (PMM2-CDG), with status active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pmm2-congenital Disorder of Glycosylation

Drugs mentioned

• GLM101 (GLM101)

Snippet

Sponsor: Glycomine, Inc. | Conditions: Phosphomannomutase 2 Deficiency, PMM2-CDG | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING